Evidence map›Paper›PMID 41668849›Full record

ArticleFrontiers in public health2026

Cross-national inequalities and public health policy effects of the global retinoblastoma burden from 1990 to 2021 and projections to 2035.

Zutong Huang, Na Zhou, Binwei Yu, Yaqun Wang, Wei Shao, Hanxiang Chen, Min Li, Ji Luo, Ni Yuan

Abstract read
In one paragraph

Article in Frontiers in public health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Zutong Huang *School of Public Health, Dalian Medical University, Dalian, Liaoning, China.
Na Zhou *School of Public Health, Peking University, Beijing, China.
Binwei YuSchool of Public Health, Dalian Medical University, Dalian, Liaoning, China.
Yaqun WangDong Fureng Institute of Economic and Social Development, Wuhan University, Wuhan, Hubei, China.
Wei ShaoLiaoning Institute of Basic Medical Sciences, Shenyang, Liaoning, China.
Hanxiang ChenTianfu College of SWUFE, Chengdu, Sichuan, China.
Min LiSchool of Public Health, Jiamusi University, Jiamusi, Heilongjiang, China.
Ji LuoThe First Hospital of China Medical University, Shenyang, Liaoning, China.
Ni YuanSchool of Public Health, Dalian Medical University, Dalian, Liaoning, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: To examine global retinoblastoma(RB) burden from 1990 to 2021, its cross-national inequalities, the effect of public health policies, and to project disease burden trends to 2035. Methods: The study examined the global, regional, and national disease burden of RB from 1990 to 2021, applying data from the Global Burden of Disease (GBD) to assess incidence, prevalence, disability-adjusted life years (DALYs), and death. Estimated annual percentage change (EAPC), connection point regression, and autoregressive moving average (ARIMA) models were used to evaluate the overall, segmented, and projection trend of the disease burden. In addition, we also examined the inequity of disease burden at various levels of the socio-demographic index (SDI) and compared the policy effects for rare diseases in countries with differing levels of socio-economic development. Results: From 1990 to 2021, the global incidence and prevalence of RB continued to rise, while the death rate and DALYs generally trended downward; however, significant differences were observed between regions and countries. By 2035, the number of incidence and prevalence is expected to decline slightly year by year, while the number of DALYs and deaths is expected to continue to rise. Countries with low Socio-demographic Index (SDI) bear a disproportionately higher disease burden. Moreover, between 1990 and 2021, absolute inequality decreased, while relative inequality increased. In addition, the impact analysis on the policy of rare diseases in countries at different levels of development shows that there is a clear correlation between a more comprehensive policy framework and the reduction of the burden of RB, among which the improvement in Central Europe is the most significant. Conclusion: The study reveals that the global burden of RB is generally in a downward trend; however, low SDI regions continue to bear a disproportionately higher burden, underscoring persistent health inequalities. Policy improvement plays a key role in reducing the burden of disease. To further narrow regional disparities and reduce the overall burden, policy building needs to be strengthened globally, particularly in underdeveloped areas. The findings of this study may also provide valuable references for the prevention and treatment of other rare diseases and the promotion of health equity.

Indexed as

Global HealthHealth PolicyHealth Status DisparitiesRetinoblastomaDisability-Adjusted Life YearsGlobal Burden of DiseaseHumansIncidencePrevalenceSocioeconomic Disparities in HealthGlobal Burden of Diseasehealth inequalityrare disease policyretinoblastomasocio-demographic index

Identifiers

PMID41668849
PMCPMC12883818

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.